Biotechnology innovation, immunology, and therapeutic research by Upstream Bio
Upstream Bio advances verekirug initiatives in asthma, CRSwNP, and COPD following Q3 2026 earnings
Upstream Bio announced its financial results for the third quarter of 2026 and highlighted continued progress for its product verekirug in the treatment of severe asthma, chronic rhinosinusitis ...
Upstream Bio to present phase 2 VALIANT trial data on verekitug for severe asthma at ERS 2026
Upstream Bio has scheduled an oral presentation of its VALIANT phase 2 trial results at ERS 2026, focusing on the efficacy and safety of verekitug, a TSLP receptor antagonist, in treating severe ...
Upstream Bio announces pivotal Phase 3 plans for verekutug while stock edges lower
Upstream Bio announced plans for pivotal Phase 3 trials of verekutug in severe asthma and chronic rhinosinusitis with nasal polyps, with studies slated to begin in 2027 targeting an expanded ...
Upstream Bio plans pivotal Phase 3 trials for verekitug in severe asthma and CRSwNP
Upstream Bio has announced its pivotal Phase 3 development plans for verekitug targeting severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). After regulatory discussions with the ...
Marie Sanchirico takes charge of Medical Affairs at Upstream Bio Inc. to drive physician engagement
Upstream Bio Inc. has named Marie Sanchirico, PhD, MBA, as head of Medical Affairs in a move designed to enhance its engagement with physicians and scientific experts. Sanchirico will be ...
Pstream Bio stock rises 2.6% after Q2 results and pipeline update
Upstream Bio reported second quarter 2026 financial results. The stock is up 2.6% on the day at $7.44.Upstream Bio reported its second quarter 2026 financial results. The company also announced ...
Upstream Bio, Inc. sets Phase 3 trial for sever asthma and CRSwNP in Q1 2027
Upstream Bio, Inc. released its financial results for the second quarter of 2026 and announced continued progress in the development of its therapeutic candidate verekitug for severe asthma, ...
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements
Upstream Bio, Inc. reported new responder analyses from its Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at EAACI2026. The results indicate that most ...
Upstream Bio, Inc. leadership to share strategy at major Goldman Sachs event
Upstream Bio, Inc. will take part in the Goldman Sachs 47th Annual Global Healthcare Conference, with CEO Rand Sutherland, MD, scheduled for a fireside chat at 10:40 a.m. ET today. The event is ...
Upstream Bio, Inc. to present new Phase 2 VIBRANT trial data for verekitug at EAACI2026
Upstream Bio, Inc. will present additional analyses from the Phase 2 VIBRANT trial of its drug verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI2026 congress in ...
Upstream Bio schedules fireside chat at global healthcare event
Upstream Bio, Inc. will participate in the Goldman Sachs 47th Annual Global Healthcare Conference, set for June 10 in Miami. The company is slated for a fireside chat on Wednesday, June 10, at ...
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026
Upstream Bio, Inc. presented two new posters from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at ATS2026. The data, which included findings on ...
